It does make me wonder a bit about the independence of Japan Chemical Daily if an interviewed company can get certain text removed after original publication.
But, setting that aside, and the apparent coyness of Regeneus about nominating timelines that shareholders might be able to use as performance benchmarks, it is nevertheless encouraging that the original reference would seem to indicate (at the very least) an objective of the company to try and settle a commercial licensing deal for Progenza by the end of the CY.
zeno9
RGS Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
